Resolve
your uncertainty
Molecular tests for indeterminate thyroid nodules are the most advanced and accurate diagnostic tool to avoid unnecessary surgeries.
I want more information
Learn about ThyroidPrint
We introduce you to the key features of the ThyroidPrint test.
ThyroidPrint is a genetic test that resolves the diagnostic uncertainty for patients with indeterminate thyroid nodules. It analyzes 10 genetic markers using the Polymerase Chain Reaction (PCR) technique of a fine needle aspiration sample. Subsequently, the PCR data is analyzed by software that determines with high accuracy whether the nodule is benign or not, providing increased certainty if surgery is necessary or not.
ThyroidPrint is a genetic test that resolves the diagnostic uncertainty for patients with indeterminate thyroid nodules. It analyzes 10 genetic markers using the Polymerase Chain Reaction (PCR) technique of a fine needle aspiration sample. Subsequently, the PCR data is analyzed by software that determines with high accuracy whether the nodule is benign or not, providing increased certainty if surgery is necessary or not.
When you have been diagnosed with an indeterminate thyroid nodule, it means you are uncertain whether to undergo surgery or not. ThyroidPrint is a test that offers you and your doctor more accurate diagnosis, enabling a safe decision to remove your thyroid or not.
If you undergo the ThyroidPrint test and the result is suspicious for malignancy, the risk of cancer increases from 25% to 70%, making surgery advisable.
Alternatively, if the result is benign, the risk of cancer is reduced from 25% to less than 5%, allowing your physician to recommend follow-up, avoiding unnecessary surgery.
The risks of undergoing unnecessary thyroid surgery are diverse, which is why obtaining greater certainty that may allow avoiding the procedure and keep your thyroid is crucial.
Benefits of the ThyroidPrint test:
- Provides a improved accuracy for the diagnosis of an indeterminate nodule.
- May avoid the risks associated with thyroid surgery.
- May avoid permanent hormonal supplementation.
- May avoid unwarranted cost of unnecessary surgery.
Avoid unnecessary surgeries
Why can ThyroidPrint help you?
Before opting for diagnostic surgery, it is important to explore all diagnostic options that will provide comprehensive information so you can making a decision on the best available information. Currently, microscopic evaluation of a fine needle aspiration (FNA) of the thyroid will provide definitive diagnosis in 80% of cases. However, in the remaining 20% an indeterminate result will be reported. For this reason, current clinical guidelines suggest the use of molecular tests such as ThyroidPrint to further improve the certainty of the diagnosis.
Scientific Evidence
What do
our patients say?
Testimonial Ximena Urzua
Testimonial Macarena Bustamante
Testimonial María Sonia Herrera
Frequently Asked Questions
We are here to help you. If you can’t find the answer, please contact us, and we will resolve all your doubts.
They are techniques that allow the analysis and/or detection of gene expression or genetic sequence abnormalities at the molecular level.
It is a molecular technique that allows us to determine abnormal changes in the presence of different genes (gene expression) in our cells. It does so by amplifying these genes so we can detect these abnormalities in the gene expression in real-time.
The report is delivered within a maximum of 10 business days once the sample arrives to the central laboratory of GeneproDX.
The report with the result is sent via email.
You are eligible for ThyroidPrint if your nodule measures between 1 cm and 5 cm, the biopsy result (FNA) indicates that the nodule is categorized as Bethesda III or IV. It is always a physician who should validate your case. Call us to get more information.
It is a universal system for categorizing thyroid nodules.
- Bethesda I: Insufficient material
- Bethesda II: Benign nodule – 3% risk of cancer
- Bethesda III and IV: Indeterminate thyroid nodules – 10-30% risk of cancer
- Bethesda V: Suspicious of malignancy – 60 to 75% risk of cancer
- Bethesda VI: 98% risk of cancer
The ThyroidPrint test can resolve diagnostic uncertainty by predicting with 95% certainty whether your indeterminate Bethesda III or IV thyroid nodule is benign.
